The most important metabolic risk factors in recurrent urinary stone formers

Urology Journal

Volumn 8, Issue 2, 2011, Pages 99-106

  Parvin, Mahmoud ^a   Shakhssalim, Nasser ^a   Basiri, Abbas ^a   Miladipour, Amir Hossein ^a   Golestan, Banafsheh ^b   Torbati, Peyman Mohammadi ^a   Azadvari, Mohaddeseh ^a   Eftekhari, Sanaz ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Calcium oxalate; Hypercalciuria; Hyperoxaluria; Kidney calculi; Risk factors

Indexed keywords

CALCIUM; CALCIUM OXALATE; CALCIUM PHOSPHATE; CHLORIDE; CITRIC ACID; CREATININE; POTASSIUM; SODIUM; URIC ACID;

ADULT; ARTICLE; HUMAN; MALE; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR; URINE; UROLITHIASIS;

ADULT; CALCIUM; CALCIUM OXALATE; CALCIUM PHOSPHATES; CHLORIDES; CITRIC ACID; CREATININE; HUMANS; MALE; MIDDLE AGED; POTASSIUM; RECURRENCE; RISK FACTORS; SODIUM; URIC ACID; URINARY CALCULI;

EID: 80051959445     PISSN: 17351308     EISSN: 1735546X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Soucie JM, Coates RJ, McClellan W, Austin H, Thun M. Relation between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epidemiol. 1996;143:487-95.
2. Basiri A, Shakhssalim N, Khoshdel AR, Ghahestani SM, Basiri H. The demographic profile of urolithiasis in Iran: a nationwide epidemiologic study. Int Urol Nephrol. 2010;42:119-26.
3. Basiri A, Shakhssalim N, Khoshdel AR, Naghavi M. Regional and seasonal variation in the incidence of urolithiasis in Iran: a place for obsession in case finding and statistical approach. Urol Res. 2009;37:197-204.
4. Wilson DM. Clinical and laboratory approaches for evaluation of nephrolithiasis. J Urol. 1989;141:770-4.
5. Pearle MS, Pak YC. Renal calculi: A practical approach to medical evaluation and management. In: Andreucci VE, Fine LG, eds. International Yearbook of Nephrology. New York: Oxford University Press; 1996:69-80.
6. Serra A, Domingos F, Salgueiro C, Prata MM. [Metabolic evaluation of recurrent idiopathic calcium stone disease in Portugal]. Acta Med Port. 2004;17: 27-34.
7. Shakhssalim N, Kazemi B, Basiri A, et al. Association between calcium-sensing receptor gene polymorphisms and recurrent calcium kidney stone disease: a comprehensive gene analysis. Scand J Urol Nephrol. 2010;44:406-12.
8. Basiri A, Shakhssalim N, Khoshdel AR, et al. Familial relations and recurrence pattern in nephrolithiasis: new words about old subjects. Urol J. 2010;7:81-6.
9. Shakhssalim N, Gilani KR, Parvin M, et al. An assessment of parathyroid hormone, calcitonin, 1,25 (OH)2 vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors. Urol Res. 2011;39:1-7.
10. Tomson CR. Prevention of recurrent calcium stones: a rational approach. Br J Urol. 1995;76:419-24.
11. Yagisawa T, Chandhoke PS, Fan J. Comparison of comprehensive and limited metabolic evaluations in the treatment of patients with recurrent calcium urolithiasis. J Urol. 1999;161:1449-52.
12. Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med. 1995;98:50-9.
13. Jeffers DM, Carter JH, Graham GA, Highsmith AK. Preparation and testing of reagent water in the clinical laboratory. In: Gibbs EL, ed. A Critique of National Committee for Clinical Laboratory Standards Guideline C3-A3. Vol 17. 3 ed; 2002.
14. Robertson WG, Hughes H. Importance of mild hyperoxaluria in the pathogenesis of urolithiasis--new evidence from studies in the Arabian peninsula. Scanning Microsc. 1993;7:391-401; discussion -2.
15. Stitchantrakul W, Kochakarn W, Ruangraksa C, Domrongkitchaiporn S. Urinary risk factors for recurrent calcium stone formation in Thai stone formers. J Med Assoc Thai. 2007;90:688-98.
16. Deshmukh SR, Khan ZH. Evaluation of urinary abnormalities in nephrolithiasis patients from Marathwada region. Indian Journal of Clinical Biochemistry. 2006;21:177-80.
17. Siener R, Glatz S, Nicolay C, Hesse A. Prospective study on the efficacy of a selective treatment and risk factors for relapse in recurrent calcium oxalate stone patients. Eur Urol. 2003;44:467-74.
18. Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int. 2001;59:2290-8.
19. Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73:489-96.
20. Netelenbos JC, Zwijnenburg PJ, ter Wee PM. Risk factors determining active urinary stone formation in patients with urolithiasis. Clin Nephrol. 2005;63: 188-92.
21. Hess B, Hasler-Strub U, Ackermann D, Jaeger P. Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis. Nephrol Dial Transplant. 1997;12:1362-8.
22. Babic-Ivancic V, Avdagic SC, Seric V, et al. Metabolic evaluation of urolithiasis patients from eastern Croatia. Coll Antropol. 2004;28:655-66.
23. del Valle E, Spivacow R, Zanchetta JR. [Metabolic changes in 2612 patients with nephrolithiasis]. Medicina (B Aires). 1999;59:417-22.
24. Coe FL. Hyperuricosuric calcium oxalate nephrolithiasis. Kidney Int. 1978;13:418-26.
25. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315:1386-9.
26. Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest. 2005;115:2598-608.
27. Menon M, Mahle CJ. Urinary citrate excretion in patients with renal calculi. J Urol. 1983;129:1158-60.
28. Pak CY, Fuller C. Idiopathic hypocitraturic calciumoxalate nephrolithiasis successfully treated with potassium citrate. Ann Intern Med. 1986;104:33-7.
29. Pak CY, Fuller C, Sakhaee K, Preminger GM, Britton F. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol. 1985;134:11-9.
30. Khan SR, Hackett RL. Hyperoxaluria, enzymuria and nephrolithiasis. Contrib Nephrol. 1993;101:190-3.
31. Wilson DR, Strauss AL, Manuel MA. Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis. Urol Res. 1984;12:39-40.
32. Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol. 1988;139:679-84.
33. Ogawa Y, Yonou H, Hokama S, Oda M, Morozumi M, Sugaya K. Urinary saturation and risk factors for calcium oxalate stone disease based on spot and 24- hour urine specimens. Front Biosci. 2003;8:a167-76.
34. Marangella M, Daniele PG, Ronzani M, Sonego S, Linari F. Urine saturation with calcium salts in normal subjects and idiopathic calcium stone-formers estimated by an improved computer model system. Urol Res. 1985;13:189-93.
35. Coe FL, Wise H, Parks JH, Asplin JR. Proportional reduction of urine supersaturation during nephrolithiasis treatment. J Urol. 2001;166:1247-51.